GlassScriptPhysician profile
Masood A Khan
NPI 1447784517
$4,264.62
in general payments reported to CMS, 2019-2025
30 companies · $1,259 in 2025
The $1,259 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $420 · 2023: $1,345 · 2024: $1,242 · 2025: $1,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,822 · Education: $23.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,821.84 |
| Education | $23.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $784.73 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $677.97 | 2022-2025 | |
| Novo Nordisk INC | $396.14 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $383.83 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $359.31 | 2022-2025 | Evenity, Prolia, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.19 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $239.11 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Exact Sciences Corporation | $168.46 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $153.18 | 2023-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.17 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $82.64 | 2023-2024 | Xarelto |
| Phathom Pharmaceuticals, INC. | $80.90 | 2024-2025 | Voquezna |
| Pfizer INC. | $54.76 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $52.28 | 2024-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Nestle Healthcare Nutrition INC. | $52.13 | 2022-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $51.84 | 2022-2023 | Airduo Digihaler |
| Esperion Therapeutics, INC. | $38.23 | 2024-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $37.68 | 2025 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $34.78 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.51 | 2023 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $27.74 | 2022 | |
| Axsome Therapeutics, INC. | $25.08 | 2024 | Auvelity |
| Astellas Pharma US INC | $24.13 | 2023 | Veozah |
| Idorsia Pharmaceuticals US INC | $23.44 | 2023 | Quviviq |
| Sobi, INC | $23.29 | 2023 | |
| Inspire Medical Systems, INC. | $20.61 | 2024 | Inspire |
| Actelion Pharmaceuticals US, INC. | $20.48 | 2024 | Opsumit, Uptravi |
| Kowa Pharmaceuticals America, INC. | $14.76 | 2025 | Zoryve |
| Currax Pharmaceuticals LLC | $13.75 | 2024 | Onzetra Xsail, Contrave |
| Lucid Diagnostics INC. | $13.50 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Masood Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.